|
KarXT Clinical Trials
8 actively recruiting trials across 5 locations
No change since May 2026
Also known as: BMS-986510, Xanomeline and Trospium Chloride capsule, BMS-986510, Xanomeline/Trospium Chloride
Pipeline
Phase 3: 8
Top Sponsors
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company4
- Bristol-Myers Squibb4
Indications
- Alzheimer's Disease8
- Psychosis Associated With Alzheimer's Disease3
- Alzheimer Disease3
- Agitation1
- Psychosis1
Chandler, Arizona3 trials
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Local Institution - 1116
Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Chandler Clinical Trials, LLC
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Local Institution - 2609
Phase 3
Homewood, Alabama2 trials
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Local Institution - 1029
Phase 3
Gilbert, Arizona1 trial
Fullerton, California1 trial
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Fullerton Neurology and Headache Center
Phase 3
Long Beach, California1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.